First patients to soon benefit from Arvelle Therapeutics’ therapy

Arvelle Therapeutics is an emerging biopharmaceutical company responsible for the development and commercialisation of cenobamate – an investigational antiepileptic drug for treating patients suffering from CNS disorders – in the European market. Cenobamate was discovered by SK Biopharmaceuticals and SK life science and is a new FDA-approved antiseizure medication (ASM) for the treatment of partial-onset seizures in adults (also known as focal-onset seizures). Cenobamate has been approved in the U.S. where it is commercially available under the trademark XCOPRI. The European Medicines Agency has already accepted the Marketing Authorization Application for Cenobamate in the European market.

The start-up has now entered a partnership with Durbin Group. Durbin is the world’s leading specialist medical supplier that works in collaboration with global Pharmaceutical and Biotech companies providing Expanded Access Programs in over 160 countries.  Under the terms of their partnership, Durbin will be responsible for the distribution of cenobamate through a Managed Access Program (MAP) in Europe. Throgh the program  patients with drug-resistant focal onset seizures that have a physician-assessed clinical need may be eligible to receive treatment with cenobamate before its commercial availability.

Commenting on the partnership, Ilise Lombardo MD, Co-Founder and Chief Medical Officer at Arvelle Therapeutics, said: “Over the past months we have received requests by European epileptologists with requests for access to cenobamate, indicating a high unmet need. As a result of increasing requests, we have selected a partner with extensive pan-European experience and regulatory expertise to support us with the MAP distribution. We are very pleased to partner with Durbin on this program.”

(Press release/RAN)